HB Wealth Management’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$12.3M Buy
50,440
+203
+0.4% +$44K 0.07% 149
2026
Q1
$8.49M Buy
50,237
+16,135
+47% +$2.79M 0.06% 179
2025
Q4
$6.23M Sell
34,102
-6,104
-15% -$852K 0.04% 227
2025
Q3
$4.88M Buy
40,206
+15,266
+61% +$1.72M 0.03% 257
2025
Q2
$2.6M Sell
24,940
-30,090
-55% -$3.19M 0.02% 326
2025
Q1
$6.42M Buy
+55,030
New +$6.27M 0.05% 184

Other funds holding AXSM

HB Wealth Management's AXSM Position: Q2 2026 in Review

HB Wealth Management increased its Axsome Therapeutics (AXSM) stake by 0.4% in Q2 2026, buying an estimated $44K and bringing the position to 50,440 shares worth $12.3M. The position accounts for 0.07% of the portfolio, ranked #149.

HB Wealth Management first reported a position in AXSM in Q1 2025 and has held it in 6 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • HB Wealth Management held 50,440 shares of Axsome Therapeutics worth $12.3M as of Q2 2026.
  • HB Wealth Management bought 203 Axsome Therapeutics shares in Q2 2026, an estimated $44K.
  • Axsome Therapeutics made up 0.07% of HB Wealth Management's portfolio in Q2 2026, its #149 holding.
  • HB Wealth Management first reported a position in Axsome Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on HB Wealth Management's 13F filing for Q2 2026, filed 29 Jul 2026.